Inhibition of CYP3A4 and CYP2C9 by podophyllotoxin: Implication for clinical drug–drug interactions

被引：0
|
作者：
Jin-Hui Song
Dong-Xue Sun
Bin Chen
Dai-Hong Ji
Jie Pu
Jie Xu
Feng-De Tian
Lin Guo
机构：
[1] Affiliated Zhongshan Hospital of Dalian University,Orthopedics Department 2
[2] Shenyang Pharmaceutical University,School of Traditional Chinese Medicine
[3] Affiliated Zhongshan Hospital of Dalian University,The Nursing Department
来源：
Journal of Biosciences | 2011年 / 36卷
关键词：
Cytochrome P450 (CYP); drug–drug interaction (DDI); podophyllotoxin (PPT); time-dependent inhibition (TDI);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Podophyllotoxin (PPT) and its derivatives exert significant anti-cancer activities, and one derivative etoposide is often utilized to treat various cancers in the clinic. The aim of the present study is to investigate the inhibitory effects of PPT on major cytochrome P450 (CYP) isoforms in human livers. Inhibition of CYP3A4, CYP2C9, CYP2C8, CYP2D6, CYP2E1 and CYP2A6 by PPT was investigated in the human liver microsomal system. Time-dependent inhibition of CYP3A4 by PPT was also evaluated. The results showed that PPT strongly exhibited inhibitory effects on CYP3A4 and CYP2C9 in a concentration-dependent manner. Half inhibition concentration (IC50) was 1.1 ± 0.3 and 4.6 ± 0.3 μM for CYP3A4 and CYP2C9, respectively. Inhibition kinetic analysis showed that PPT exhibited competitive inhibition towards CYP3A4 and CYP2C9 with Ki of 1.6 and 2.0 μM, respectively. Additionally, PPT exerted time-dependent inhibition towards CYP3A4 and the kinetic parameters were 4.4 ± 2.1 μM and 0.06 ± 0.01 min–1 for KI and kinact, respectively. Our experimental data indicate that potential drug–drug interaction (DDI) might exist when PPT is co-administered with the substrates which mainly undergo CYP3A4- or CYP2C9-mediated metabolism.
引用
收藏
页码：879 / 885
页数：6
相关论文
共 50 条
  • [41] Evaluation of Selected Malaysian Medicinal Plants on Phase I Drug Metabolizing Enzymes, CYP2C9, CYP2D6 and CYP3A4 Activities in vitro
    Hanapi, N. A.
    Azizi, J.
    Ismail, S.
    Mansor, S. M.
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2010, 6 (04) : 494 - 499
  • [42] Inhibition of CYP2C9 by natural products: insight into the potential risk of herb-drug interactions
    Wang, Kai
    Gao, Qing
    Zhang, Tingting
    Rao, Jinqiu
    Ding, Liqin
    Qiu, Feng
    DRUG METABOLISM REVIEWS, 2020, 52 (02) : 235 - 257
  • [43] Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction
    Fang, Zhong-Ze
    Zhang, Yan-Yan
    Ge, Guang-Bo
    Huo, Hong
    Liang, Si-Cheng
    Yang, Ling
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (02) : 193 - 199
  • [44] Implication of genetic polymorphisms in CYP2C9 and CYP2C19 on drug metabolism in isolated cryopreserved human hepatocytes
    Tolondo, Roberto
    Brown, Caitlin
    Heyward, Scott
    DRUG METABOLISM REVIEWS, 2010, 42 : 262 - 262
  • [45] CONTRIBUTION OF UGT1A1, CYP2A6, CYP2C9, AND CYP3A4 IN METABOLISM OF BELINOSTAT
    Luo, Gang
    Schicker, Michael
    Lee, Deborah
    Leitz, Sara
    McKenzie, Donald
    Albaugh, Daniel
    Reddy, Guru
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : S59 - S59
  • [46] Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs
    Nomoto, Maiko
    Zamora, Cynthia A.
    Schuck, Edgar
    Boyd, Peter
    Chang, Min-Kun
    Aluri, Jagadeesh
    Siu, Y. Amy
    Lai, W. George
    Yasuda, Sanae
    Ferry, Jim
    Rege, Bhaskar
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (05) : 952 - 960
  • [47] In vitro interactions of abiraterone, erythromycin, and CYP3A4: implications for drug-drug interactions
    Masamrekh, Rami A.
    Kuzikov, Alexey V.
    Haurychenka, Yaraslau I.
    Shcherbakov, Kirill A.
    Veselovsky, Alexander V.
    Filimonov, Dmitrii A.
    Dmitriev, Alexander V.
    Zavialova, Maria G.
    Gilep, Andrei A.
    Shkel, Tatsiana V.
    Strushkevich, Natallia V.
    Usanov, Sergey A.
    Archakov, Alexander I.
    Shumyantseva, Victoria V.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2020, 34 (01) : 120 - 130
  • [48] Predicting Drug-Drug Interactions Involving the Inhibition of Intestinal CYP3A4 and P-Glycoprotein
    Tachibana, Tatsuhiko
    Kato, Motohiro
    Takano, Junichi
    Sugiyama, Yuichi
    CURRENT DRUG METABOLISM, 2010, 11 (09) : 762 - 777
  • [49] Drug-drug interactions by azole antifungals: Beyond a dogma of CYP3A4 enzyme activity inhibition
    Dvorak, Zdenek
    TOXICOLOGY LETTERS, 2011, 202 (02) : 129 - 132
  • [50] ASSESSMENT OF A BASIC MODEL FOR PREDICTING POTENTIAL CLINICAL DRUG INTERACTIONS MEDIATED BY CYP3A4 INHIBITION.
    Qosa, H.
    Avaritt, B.
    Volpe, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S43 - S43
12345